Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience
Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience
复制标题
DOI：
10.1007/s00198-008-0698-8
复制
发表时间：
2009-04-01
影响因子：
4
通讯作者：
Roux, C.
中科院分区：
文献类型：
--
作者：
Briot, K.;Ravaud, P.;Roux, C.
这项研究评估了5413名参加教育和随访计划的绝经后骨质疏松症妇女服用特瑞帕帝18个月的持久性。分析表明，遵循该方案的妇女的持续率为81.5%，高于现有的口服抗吸收治疗。2004年9月在法国推出特瑞帕替德后，制定了教育和后续计划，以帮助妇女跟随治疗。这项研究的目的是评估接受该计划的绝经后骨质疏松症妇女服用特瑞帕帝的持久性。有关持久性的数据可从2004年9月至2007年6月期间获得。持续性被定义为18个月疗程结束时仍在接受治疗的患者的百分比，并与法国全民医疗保险制度提供的数据进行了比较。自2004年9月在法国推出teriparatide以来，5413名患有骨质疏松症和脊椎骨折(平均3.9+/-2岁)的绝经后女性(平均年龄72.3±14.5岁)参加了该计划。15个月的持续率为81.5%，我们的分析表明，大多数患者完成了18个月的疗程。停药的主要原因是不良反应(46.7%)。法国全民健康保险的数据显示，没有参加该计划的妇女的持久性可能接近0%。接受特瑞帕帝治疗并参加教育和后续计划的绝经后骨质疏松症妇女的持久性很高。
This study evaluated the 18-month persistence with teriparatide in 5413 postmenopausal osteoporotic women who were enrolled in an education and follow-up program. Analysis showed that the persistence rate was 81.5% for women who follow the program, higher than for existing oral antiresorptive treatments.An education and follow-up program was developed after launch of teriparatide in France in September 2004, to help women to follow the treatment. The objective of this study was to evaluate the persistence with teriparatide in postmenopausal osteoporotic women following this program.Data about persistence are available for the period September 2004 to June 2007. Persistence is defined as the percentage of patients still on treatment at the end of the 18-month course, and it has been compared to the data provided by the French universal health insurance system.Since the launch of teriparatide in France in September 2004, 5413 postmenopausal women (mean age 72.3 +/- 14.5 years) with osteoporosis and vertebral fractures (mean 3.9 +/- 2) have participated in the program. The persistence rate at 15 months was 81.5%, and our analysis suggested that a majority of patients completed the 18-month treatment course. The main reason for discontinuation was adverse events (46.7%). Data of the French Universal Health Insurance suggest that the persistence may be close to 0% for women who are not in the program.Postmenopausal osteoporotic women treated by teriparatide and enrolled in an education and follow-up program have a high persistence rate.